GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » Institutional Ownership

Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Institutional Ownership : 0.01% (As of Apr. 12, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biocytogen Pharmaceuticals (Beijing) Co's institutional ownership is 0.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biocytogen Pharmaceuticals (Beijing) Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biocytogen Pharmaceuticals (Beijing) Co's Float Percentage Of Total Shares Outstanding is 0.00%.


Biocytogen Pharmaceuticals (Beijing) Co Institutional Ownership Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Institutional Ownership Chart

Biocytogen Pharmaceuticals (Beijing) Co Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co can be seen below:

2023-02-28 2023-03-31 2023-04-30 2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30
Institutional Ownership 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01

Biocytogen Pharmaceuticals (Beijing) Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Biocytogen Pharmaceuticals (Beijing) Co Business Description

Traded in Other Exchanges
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines